Segment Information (Details) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2024
USD ($)
|
Sep. 30, 2025
USD ($)
segment
|
Sep. 30, 2024
USD ($)
|
|
| Segment Reporting [Abstract] | ||||
| Number of operating segments | segment | 1 | |||
| Segment Reporting, Asset Reconciling Item [Line Items] | ||||
| License and other revenue | $ 0 | $ 0 | $ 15,000 | $ 0 |
| Other R&D expenses: | ||||
| General and administrative expenses | (12,227) | (12,502) | (36,473) | (37,105) |
| Share-based compensation | 7,194 | 8,453 | 23,026 | 25,218 |
| Interest and investment income | 3,765 | 3,340 | 16,035 | 9,171 |
| Interest expense | (2,890) | (2,557) | (8,651) | (7,611) |
| Income tax expense | (166) | (608) | (2,341) | (1,794) |
| Consolidated net loss | (54,891) | (42,566) | (131,369) | (124,428) |
| Reportable Segment | ||||
| Segment Reporting, Asset Reconciling Item [Line Items] | ||||
| License and other revenue | 0 | 0 | 15,000 | 0 |
| Less: | ||||
| OX2R agonist program expenses | (35,562) | (11,744) | (88,336) | (26,696) |
| LockBody program expenses | (3,441) | (2,815) | (8,624) | (9,081) |
| Discontinued R&D program expenses | 585 | (16,165) | (3,524) | (44,784) |
| Other R&D expenses: | ||||
| Personnel expenses | (7,370) | (4,393) | (19,749) | (14,893) |
| Research tax incentives | 9,321 | 5,500 | 18,055 | 18,895 |
| Other preclinical and clinical development expenses | (1,798) | (644) | (3,999) | (1,438) |
| General and administrative expenses | (8,331) | (7,691) | (25,017) | (23,260) |
| Share-based compensation | (7,194) | (8,453) | (23,026) | (25,218) |
| Interest and investment income | 3,765 | 3,340 | 16,035 | 9,171 |
| Interest expense | (2,890) | (2,557) | (8,651) | (7,611) |
| Other segment items | (1,810) | 3,664 | 2,808 | 2,281 |
| Income tax expense | (166) | (608) | (2,341) | (1,794) |
| Consolidated net loss | $ (54,891) | $ (42,566) | $ (131,369) | $ (124,428) |
| X | ||||||||||
- Definition Discontinued Research And Development Expenses No definition available.
|
| X | ||||||||||
- Definition Other R&D Expenses No definition available.
|
| X | ||||||||||
- Definition Research And Development Expense, Program No definition available.
|
| X | ||||||||||
- Definition Research And Development Expense, Tax Incentives No definition available.
|
| X | ||||||||||
- Definition Research And Development Expense, Technology Platform No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|